Pancreatic Cancer Clinical Trials in Pittsburgh

Showing 81-100 of 143 trials

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

NCT01845805

To improve progression free survival in high risk patients with resected pancreatic adenocarcinoma who have node positive disease, margin positive disease, and/or elevation in CA 19-9 treated with CC-486 (oral azacitidine) as compared to observation after completion of adjuvant therapy.

Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins49 participantsStarted Jan 2014

Baltimore, Maryland, United States • Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States +1 more locations

COMPLETEDPhase 2< 1 mile

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

NCT03040986

This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or other places in the body. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

KRAS NP_004976.2:p.G12RStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7

National Cancer Institute (NCI)8 participantsStarted Jul 2017

Los Angeles, California, United States • Los Angeles, California, United States • Sacramento, California, United States +6 more locations

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Pancreatic Cancer Trials in Other Cities

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Immunotherapy Study for Surgically Resected Pancreatic Cancer

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Vaccine Study for Surgically Resected Pancreatic Cancer

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options

Other Conditions in Pittsburgh